Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy.
JAMA., Nov:1-10 (2012)
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
JAMA., Nov;308(17):1785-94 (2012)
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Pharmacogenet. Genomics., Jan;23(1):1-8 (2013)
Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention.
Int. J. Cardiol., Oct (2012)
Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y(12) receptor inhibitors.
Expert Rev Cardiovasc Ther., Aug;10(8):1011-22 (2012)
Platelet reactivity and thrombogenicity in postmenopausal women.
Menopause., Sep (2012)
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
N. Engl. J. Med., Oct;367(14):1297-309 (2012)
Pharmacogenetic guidance for antiplatelet treatment.
Lancet., Aug;380(9843):725; author reply 725-6 (2012)
Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention.
Diabetes Care., Nov;35(11):2194-7 (2012)
Clopidogrel efficacy and cigarette smoking status.
JAMA., Jun;307(23):2495-6 (2012)
Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
Am. Heart J., Jul;164(1):35-42 (2012)
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
Expert Opin Pharmacother., Aug;13(12):1771-96 (2012)
Antiplatelet therapy beyond 2012: role of personalized medicine.
Pol. Arch. Med. Wewn., 122(6):298-305 (2012)
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC
Circ Cardiovasc Interv., Jun;5(3):336-46 (2012)
Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity.
Platelets., May (2012)
Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Cardiol J., 19(3):230-42 (2012)
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
Thromb. Haemost., Jul;108(1):12-20 (2012)
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I
Circ Cardiovasc Interv., Jun;5(3):347-56 (2012)
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Clin Pharmacokinet., Jun;51(6):397-409 (2012)
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Eur. Heart J., Sep;33(17):2151-62 (2012)